Stock explainer / Pharmaceuticals
AstraZeneca stock, explained for beginners
Reviewed 11 October 2026
The short answer
AstraZeneca discovers, develops and sells prescription medicines, with a large focus on cancer, cardiovascular, kidney, respiratory and rare diseases.
Investing involves risk and you can lose money. This page explains general ideas; it is not personal financial, tax or investment advice.
AstraZeneca is a UK-based pharmaceutical company with medicines in cancer, heart and kidney disease, respiratory illness and rare diseases. It is one of the largest companies in the FTSE 100.
Like all drug makers, its future depends on research success, regulatory approvals and replacing medicines as their patents expire.
How AstraZeneca makes money
- Sales of patented prescription medicines
- Oncology medicines, a major growth area
- Partnerships and licensing
Main strengths
- A broad range of medicines
- A substantial research pipeline
- Global sales
Main risks
- Clinical trial failures
- Patent expiries and generic competition
- Government pressure on drug prices
Five questions to ask about AstraZeneca
These match Mesodian's five core scores. Members see each score, updated, with the factors behind it.
- Quality
- How profitable is it after heavy research spending?
- Growth
- Can new medicines replace those losing patents?
- Value
- What are investors paying for its expected growth?
- Sentiment
- How do analysts view its pipeline?
- Risk
- How concentrated are its sales in a few medicines?
This explainer is general education about a well-known company. It is not a recommendation to buy, sell or hold AZN. Check the company's latest reports before making decisions.
Keep going
Learn as you invest, with Mesodian.
Lessons, five plain-English scores and a clear view of your portfolio. Research is €9.99 a month; Premium, with broker connection and portfolio tracking, is €14.99.